Calithera Biosciences Statistics
Share Statistics
Calithera Biosciences has 4.87M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 4.87M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.83M |
| Failed to Deliver (FTD) Shares | 237 |
| FTD / Avg. Volume | 8.01% |
Short Selling Information
The latest short interest is 417.28K, so 8.56% of the outstanding shares have been sold short.
| Short Interest | 417.28K |
| Short % of Shares Out | 8.56% |
| Short % of Float | 8.64% |
| Short Ratio (days to cover) | 0.78 |
Valuation Ratios
The PE ratio is -0.86 and the forward PE ratio is null.
| PE Ratio | -0.86 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 0.8 |
| P/FCF Ratio | -0.37 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Calithera Biosciences Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.6, with a Debt / Equity ratio of 0.
| Current Ratio | 3.6 |
| Quick Ratio | 3.6 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.93% and return on capital (ROIC) is -90.76%.
| Return on Equity (ROE) | -0.93% |
| Return on Assets (ROA) | -0.66% |
| Return on Capital (ROIC) | -90.76% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.36M |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -20.78M |
| Effective Tax Rate | 0.52 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -1.13, so Calithera Biosciences 's price volatility has been lower than the market average.
| Beta | -1.13 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 39.68 |
| Average Volume (20 Days) | 2.96K |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.39M |
| Operating Income | -42.07M |
| Net Income | -18.87M |
| EBITDA | -38.27M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -7.94 |
Balance Sheet
The company has 25.45M in cash and 1.67M in debt, giving a net cash position of 23.79M.
| Cash & Cash Equivalents | 25.45M |
| Total Debt | 1.67M |
| Net Cash | 23.79M |
| Retained Earnings | -512.62M |
| Total Assets | 28.68M |
| Working Capital | 19.23M |
Cash Flow
In the last 12 months, operating cash flow was -43.61M and capital expenditures -133.00K, giving a free cash flow of -43.74M.
| Operating Cash Flow | -43.61M |
| Capital Expenditures | -133.00K |
| Free Cash Flow | -43.74M |
| FCF Per Share | -8.76 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CALA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | -2991860.47% |
Analyst Forecast
Currently there are no analyst rating for CALA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jun 15, 2022. It was a backward split with a ratio of 1:20.
| Last Split Date | Jun 15, 2022 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -28.81 |
| Piotroski F-Score | 0 |